WASHINGTON (CN) - Cephalon illegally restrained commerce by buying off four generic competitors with more than $200 million to delay generic competition for its wakefulness drug, Provigil, until 2012, the FTC claims in Federal Court. Provigil's antitrust violations will cost consumers "hundreds of millions of dollars a year," the FTC says.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026